Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.

Paul S CalaraJenny M NorlinRikard AlthinKatarina Steen CarlssonMarcus Schmitt-Egenolf

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2016)

Disease severity does not explain the decision to switch or not to switch to biologics for a disproportionate number of patients. There seems to be an uneven uptake of biologics in Swedish clinical practice, but the type of healthcare provider cannot explain this variation. More research is needed on what factors influence the prescription of biologics.

Keyphrases

healthcare
primary care
clinical practice
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
decision making
patient reported outcomes
affordable care act